This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ERB-041
Description: ERB-041 is a potent and highly selective estrogen receptor (ER) beta agonist that has comparable binding affinity for ERbeta as the natural ligand (17beta-estradiol), but is >200-fold selective over ERalpha.
Deal Structure: ERB-041 was originally developed by Wyeth.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.
Additional information available to subscribers only: